The KEYMAKER-U03 Substudy 03B evaluated pembrolizumab-based immunotherapy combinations in advanced clear cell renal cell carcinoma (ccRCC) after progression on PD-(L)1 and VEGF-TKI therapies.
Results show that pembrolizumab + quavonlimab (anti-CTLA-4) and pembrolizumab + lenvatinib demonstrated antitumor activity, while other investigational combinations did not yield significant clinical benefits. The safety profile remained manageable across treatment arms.
These findings inform the future of immunotherapy strategies in ccRCC and highlight the importance of further research into targeted combinations.
A big thank you to the experts for their dedication to improving treatment options for ccRCC.
Read more:https://lnkd.in/eUjTaeDh
